Company Overview - Upstream Bio, Inc. is a clinical-stage biotechnology company focused on developing treatments for inflammatory diseases, particularly severe respiratory disorders [3] - The company is advancing verekitug, a monoclonal antibody targeting the receptor for thymic stromal lymphopoietin (TSLP), which is involved in inflammatory responses [3] - Verekitug is currently in separate Phase 2 trials for chronic rhinosinusitis with nasal polyps (CRSwNP), severe asthma, and chronic obstructive pulmonary disease (COPD) [3] Upcoming Events - Rand Sutherland, MD, CEO of Upstream Bio, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, at 2:15 p.m. PT [1] - A live webcast of the presentation will be available on Upstream Bio's website, with a replay accessible afterward [2]
Upstream Bio to Present at the 44th Annual J.P. Morgan Healthcare Conference